Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
US Army
UBS
Chubb
Deloitte
Citi
Federal Trade Commission
Merck
Colorcon

Generated: August 19, 2018

DrugPatentWatch Database Preview

Minocycline hydrochloride - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic sources for minocycline hydrochloride and what is the scope of minocycline hydrochloride freedom to operate?

Minocycline hydrochloride is the generic ingredient in seven branded drugs marketed by Sun Pharm Inds Ltd, Cnty Line Pharms, Precision Dermat, Triax Pharms, Aurobindo Pharma, Impax Labs, Sun Pharm Inds Inc, Torrent Pharma Inc, Watson Labs, Watson Labs Teva, Zydus Worldwide, Lederle, Rempex Pharms, Orapharma, Alkem Labs Ltd, Aurobindo Pharma Ltd, Barr Labs Inc, Impax Labs Inc, Lupin Ltd, Mylan Pharms Inc, Sandoz, Sidmak Labs India, Zydus Pharms Usa Inc, Dr Reddys Labs Ltd, Medicis, Par Pharm, and Sun Pharm Industries, and is included in thirty-four NDAs. There are thirteen patents protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Minocycline hydrochloride has fifty-six patent family members in twenty-six countries.

There are fourteen drug master file entries for minocycline hydrochloride. Fifty-one suppliers are listed for this compound. There are seven tentative approvals for this compound.

Pharmacology for minocycline hydrochloride
Ingredient-typeTetracyclines
Drug ClassTetracycline-class Drug
Medical Subject Heading (MeSH) Categories for minocycline hydrochloride
Synonyms for minocycline hydrochloride
(2E,4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione hydrochloride
(2Z,4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione hydrochloride
(4S-(4alpha,4aalpha,5aalpha,12aalpha))-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxonaphthacene-2-carboxamide monohydrochloride
(4S,12aS,4aS,5aR)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4,5,6,12a,4a,5a-hexahydronaphthacene-2-carboxamide Hydrochloride
(4S,4aS,5aR,12aS)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide hydrochloride
[4S-(4?,4a?,5a?,12a?)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a,tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
[4S-(4|A,4a|A,5a|A,12a|A)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydro-1,11-dioxo-2-naphthacenecarboxamide Hydrochloride
[4S-(4|A,4a|A,5a|A,12a|A)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxonaphthacene-2-carboxamide monohydrochloride
[4S-(4a,4aa,5aa,12aa)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a,tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
[4S-(4alpha,4aalpha,5aalpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxonaphthacene-2-carboxamide monohydrochloride
[4S-(4alpha,4aalpha,5aalpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxonaphthacene-2-carboxamide monohydrochloride;[4S-(4alpha,4aalpha,5aalpha,12aalpha)]-4,7-Bis(dimeth
0020414E5U
10118-90-8 (base)
10118-90-8 (Parent)
1071702-75-4
11006-27-2
1236362-29-0
13614-98-7
150231-24-6
2-Naphthacenecarboxamide, 4,7- bis(dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-1,11dioxo-, monohydrochloride, [4S-(4alpha,4aalpha,5aalpha,12aalpha)]
2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, monohydrochloride
2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, monohydrochloride, (4S-(4alpha,4aalpha,5aalpha,12aalpha))-
4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide monohydrochloride
614M987
7-Dimethylamino-6-demethyl-6-deoxytetracycline, HCl
AB1009463
AC-22362
AC1NQY0N
AC1NSG07
Acnez
AK144731
AKOS015951312
Arestin
Arestin (TN)
BC207859
C23H27N3O7.HCl
C23H28ClN3O7
CAS-13614-98-7
CCG-40107
CHEBI:50697
CHEMBL1200881
CS-1256
D00850
DSSTox_CID_24545
DSSTox_GSID_44545
DSSTox_RID_80306
DTXSID8044545
Dynacin
Dynacin (TN)
EINECS 237-099-7
FT-0082736
FT-0601821
FXFM-244
GLMUAFMGXXHGLU-VQAITOIOSA-N
HMS1568P12
HY-17412
J10198
KB-274624
Klinomycin
KS-00000XT8
Lederderm
LS-91518
LS-93852
M2288
MFCD00083669
Minocin
Minocin (TN)
Minocycline (hydrochloride)
Minocycline chloride
Minocycline HCl
Minocycline hydrochloride (internal use)
Minocycline hydrochloride (JP17/USP)
Minocycline hydrochloride [USAN:JAN]
Minocycline hydrochloride [USP:JAN]
Minocycline hydrochloride, Antibiotic for Culture Media Use Only
Minocycline hydrochloride, crystalline
Minocycline hydrochloride, European Pharmacopoeia (EP) Reference Standard
Minocycline Hydrochloride, pharmaceutical secondary standard; traceable to USP, PhEur, BP
Minocycline hydrochloride, United States Pharmacopeia (USP) Reference Standard
Minocycline, Hydrochloride
Minomax
Minomycin
MLS002548863
MolPort-003-666-235
MolPort-042-652-589
Mynocine
Mynocine hydrochloride
NC00460
NCGC00096006-01
NCGC00178854-03
NCGC00255988-01
NSC 141993
NSC-757120
NSC757120
Periocline
Pharmakon1600-01500414
Prestwick_626
Q-201407
S051
s4226
SC-19210
SCHEMBL2537
SMR001906766
Solodyn
Solodyn (TN)
SPECTRUM1500414
ST24034766
Tox21_111250
Tox21_111250_1
Tox21_113183
Tox21_301590
Tri-mino
Tri-minocycline
UNII-0020414E5U
Vectrin
W-5076
Tentative approvals for MINOCYCLINE HYDROCHLORIDE
Applicant Application No. Strength Dosage Form
➤ Try a Free Trial➤ Try a Free TrialEQ 45MG BASETABLET, EXTENDED RELEASE;ORAL
➤ Try a Free Trial➤ Try a Free TrialEQ 135MG BASETABLET, EXTENDED RELEASE;ORAL
➤ Try a Free Trial➤ Try a Free TrialEQ 115MG BASETABLET, EXTENDED RELEASE;ORAL

US Patents and Regulatory Information for minocycline hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Medicis SOLODYN minocycline hydrochloride TABLET, EXTENDED RELEASE;ORAL 050808-002 May 8, 2006 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Medicis SOLODYN minocycline hydrochloride TABLET, EXTENDED RELEASE;ORAL 050808-006 Aug 27, 2010 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Medicis SOLODYN minocycline hydrochloride TABLET, EXTENDED RELEASE;ORAL 050808-002 May 8, 2006 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Rempex Pharms MINOCIN minocycline hydrochloride INJECTABLE;INJECTION 050444-001 Approved Prior to Jan 1, 1982 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Medicis SOLODYN minocycline hydrochloride TABLET, EXTENDED RELEASE;ORAL 050808-003 May 8, 2006 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Dr Reddys Labs Ltd MINOCYCLINE HYDROCHLORIDE minocycline hydrochloride TABLET;ORAL 065436-001 Dec 26, 2007 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Medicis SOLODYN minocycline hydrochloride TABLET, EXTENDED RELEASE;ORAL 050808-007 Aug 27, 2010 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for minocycline hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Medicis SOLODYN minocycline hydrochloride TABLET, EXTENDED RELEASE;ORAL 050808-008 Aug 27, 2010 ➤ Try a Free Trial ➤ Try a Free Trial
Sun Pharm Inds Ltd XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-005 Jul 11, 2012 ➤ Try a Free Trial ➤ Try a Free Trial
Sun Pharm Inds Ltd XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-001 Jul 11, 2012 ➤ Try a Free Trial ➤ Try a Free Trial
Medicis SOLODYN minocycline hydrochloride TABLET, EXTENDED RELEASE;ORAL 050808-005 Jul 23, 2009 ➤ Try a Free Trial ➤ Try a Free Trial
Medicis SOLODYN minocycline hydrochloride TABLET, EXTENDED RELEASE;ORAL 050808-001 May 8, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Medicis SOLODYN minocycline hydrochloride TABLET, EXTENDED RELEASE;ORAL 050808-002 May 8, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Sun Pharm Inds Ltd XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-003 Jul 11, 2012 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Non-Orange Book US Patents for minocycline hydrochloride

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,744,179 Tetracycline compositions ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

International Patents for minocycline hydrochloride

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Chinese Patent Office
Julphar
Covington
Cerilliant
UBS
Queensland Health
Federal Trade Commission
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.